Last reviewed · How we verify
Altabax (R)
Retapamulin is a bacterial protein synthesis inhibitor that binds to the bacterial ribosome to prevent bacterial growth.
Retapamulin is a bacterial protein synthesis inhibitor that binds to the bacterial ribosome to prevent bacterial growth. Used for Impetigo caused by susceptible strains of Staphylococcus aureus or Streptococcus pyogenes.
At a glance
| Generic name | Altabax (R) |
|---|---|
| Also known as | Altabax(R)ointment, Locoid lipocream (R) |
| Sponsor | St. Luke's-Roosevelt Hospital Center |
| Drug class | Pleuromutilin antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Retapamulin is a pleuromutilin antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is bacteriostatic, meaning it stops bacterial growth rather than directly killing bacteria. This mechanism makes it effective against gram-positive bacteria commonly responsible for skin infections.
Approved indications
- Impetigo caused by susceptible strains of Staphylococcus aureus or Streptococcus pyogenes
Common side effects
- Application site irritation
- Application site pruritus
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Altabax (R) CI brief — competitive landscape report
- Altabax (R) updates RSS · CI watch RSS
- St. Luke's-Roosevelt Hospital Center portfolio CI